Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling

Basil K Williams, Jr, MD¹, Jennifer J Siegel, PhD², Katherina M Alsina, PhD², Lauren Johnston, MSW³, Amanda Sisco, MA⁴, Kyleigh LiPira, MBA³, Sara M Selig, MD, MPH³, and Peter G Hovland, MD, PhD⁴

¹University of Cincinnati College of Medicine, Cincinnati, OH, USA ²Castle Biosciences, Inc., Friendswood, TX, USA ³Melanoma Research Foundation, Washington, DC, USA ⁴Colorado Retina Associates, Denver, CO, USA

Conflicts of interest disclosure: JJS and KMA are employee shareholders of Castle Biosciences, Inc. (CBI). BKW is a consultant for Allergan, Genentech, and CBI. PGH is a consultant for CBI. Neither BKW nor PGH received payment in relation to this study. All other authors have nothing to declare

For more information: basilkwilliams@gmail.com
Background and Survey Study Design

1. Prognostic tests including 15-gene expression profile (15-GEP), chromosome 3 status, and BAP1 mutations are used across the U.S in the management of newly diagnosed uveal melanoma (UM).

2. The objective of this study was to understand UM patient experiences following 15-GEP testing compared to patients with alternative or no prognostic testing.

**Patients with clinical diagnosis of UM**

- 15-GEP (DecisionDx-UM) N=91
  - Decision-making process N=85
  - Concerns about testing N=84
  - Value of test results N=85
  - Decision regret N=85

- Alternative Test Only N=21
  - Decision-making process N=16
  - Concerns about testing N=16
  - Value of test results N=16
  - Decision regret N=16

- Offered 15-GEP testing but opted out N=5
  - Decision-making process N=5

- Not offered prognostic testing N=47
  - Decision-making process N=45

- Did not know N=13
  - Decision-making process N=13
Desire For and Use of Prognostic Testing

A. ‘Did you want prognostic information when diagnosed?’

- Yes (90%)
- I don’t know (5%)
- No (5%)

N=177

B. ‘What kind of testing was performed?’

- 15-GEP
- Chr. 3
- BAP1
- None
- Unsure
Patients Value Test Results: ‘What do you feel you gained MOST...?’

› ...from any prognostic test: increased knowledge and understanding

› ...from 15-GEP: patients with a Class 1A result (low risk) gained a sense of relief from uncertainty about the future
Low Decision Regret\(^1\) After Prognostic Testing, Regardless of 15-GEP Class Result

- Patients had significantly more decision regret if they opted out of prognostic testing
- For 15-GEP-tested patients, no significant difference in decision regret was found across all Class results

\(^1\)Decision Regret Scale: AM O’Connor, 1996.